🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Top Research Reports For August 19, 2016

Published 08/18/2016, 11:44 PM
Updated 07/09/2023, 06:31 AM
TEVA
-
AABA
-
CMCSA
-
AGN
-

Friday, August 19, 2016

We are featuring 16 research reports in today's Research Daily, including reports on Verizon (VZ), Comcast (NASDAQ:CMCSA) and Teva Pharmaceutical (NYSE:TEVA).

Verizon shares have been weak lately, but they continued to benefit from investors' great demand for yield (it provides a juicy dividend, currently yiedling in excess of 4%). But Verizon is more than safe and stable dividend. They are actively investing into related spaces that add to their core telecom leadership. The move into online content delivery, mobile video and online advertising, with the recent Yahoo (NASDAQ:YHOO) deal as part of that strategy. (Youcan read the full research report on Verizon here>>)

Comcast's continued momentum (the stock is up 20% year-to-date) reflects the strength in its Cable business and significant improvement in the NBC Universal segment. The deals to acquire DreamWorks Animation and Icontrol Networks bode well and should help fend off competition. Also, Comcast is investing heavily in its theme park business. The company has forayed into the over-the-top video delivery market with the launch of its Internet TV service “Stream”. (You can read the full research report on Comcast here>>)

Teva Pharmaceutical shares have struggled this year as a result of investors' concerns on the generic drug maker's pipeline and stiff competitive pressures in the space. These issues notwithstanding, the analyst likes the Actavis (NYSE:AGN) Generics acquisition, which will help the company strengthen its position in key generic markets. Teva continues to progress with its branded and generics drugs pipeline and is also looking to strengthen its biosimilar pipeline. (You can read the full research report on TEVA here>>)

You can find all of today's stock research reports here >>>

Today's Private Buys & Sells from Zacks Research
While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>

Sheraz Mian

Director of Research

Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios.

If you want an email notification each time Sheraz publishes a new article, please click here >>

Featured Reports

Zoetis (ZTS) Beats on Q2 Earnings & Revenues, Lifts Outlook

Zoetis' Q2 results were strong with a beat on both fronts. The Zacks analyst believes that the raised outlook for 2016 is achievable on the back of a diversified product portfolio.

Eversource (ES) Q2 Earnings On Par, Misses Revenues

The covering analyst believes Eversource Energy's consistent investment in growth projects and cost saving initiatives will boost its performance.

Harris (HRS) Tops Q4 Earnings, Revenue Miss Cause for Concern

While positive on the earnings beat, the Zacks analyst is concerned about the revenue miss and expects top line struggles to continue due to prevalent headwinds like foreign exchange issues.

DICK'S Sporting (DKS) Ups View on Q2 Earnings & Sales Beat

According to the covering analyst, robust omni-channel growth drove DICK'S Sporting's second-quarter fiscal 2016 results that also led to a raised outlook.

AvalonBay (AVB) to Gain from demographics, Supply Woes Linger

The Zacks analyst thinks AvalonBay remains well poised to gain from higher demand of household formation and favorable demographics. Yet, high deliveries in a number of its markets raise woes.

Sun Life Financial (SLF) Suffers Due to Segmental Weaknesses

Sun Life's bottom line beat expectations but net income declined on segmental weaknesses. Yet, the company expects bottom line growth of 8% -10% and ROE of 12% - 14% over the medium term.

Dr Pepper (DPS) Q2 Earnings Robust; Ups 2016 Outlook

The Zacks analyst believes higher sales and RCI productivity gains drove robust second quarter results.

New Upgrades

SM Energy's (SM) Attempt to Improve Asset Quality Encouraging

According to the Zacks analyst, SM Energy's initiative to improve asset quality in view of improving commodity prices is likely to help it in enhancing future growth potential as well as margins.

Nabors' (NBR) Cost Reduction Initiatives Look Impressive

The covering analyst appreciates Nabors' cost reduction initiatives especially when the drilling business scenario is not favorable and is expected to deteriorate further.

Citi Trends (CTRN) Gains on Lower Than Expected Loss

The Zacks analyst is encouraged by the company's narrower-than-expected loss per share and sales beat in second-quarter fiscal 2016, alongside its robust sales outlook, which drove estimates up

New Downgrades

Celanese (CE) Faces Pricing Headwinds, Acetyl Weakness

The Zacks analyst is concerned about weak prices and sustained pressure on the company's acetyl margins. Acetyl demand remains weak in China given the sluggish economic conditions.

J.B. Hunt's (JBHT) Low Revenues and Reduced Guidance Worrying

According to the covering analyst, reduced performance outlook resulting from low fuel surcharge revenues is cause for concern, despite introduction of asset light transportation models.

Lowe's (LOW) Subdued Earnings Outlook Raises Concern

The Zacks analyst remains concerned about Lowe's dismal performance in the second quarter of 2016 and subdued earnings outlook. However, expected sales growth of 10% provides some cushion to the stock



ZOETIS INC (ZTS): Free Stock Analysis Report

VERIZON COMM (VZ): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

LOWES COS (LOW): Free Stock Analysis Report

COMCAST CORP A (CMCSA): Free Stock Analysis Report

AVALONBAY CMMTY (AVB): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.